Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshReset Filter
              refresh Reset Filter
              price-trend All Drugs in Dev.

              Product Type

              Companies

              AbbVie Inc

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              Contact Supplier Contact Supplier
              Flag United States
              Virtual Booth Virtual Booth

              20th Annual Contact Pharma

              Participation Not Confirmed

              Update your events

              Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Hig...

              Lead Product(s): Venetoclax,Azacitidine

              Therapeutic Area: Oncology Product Name: Venclyxta

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 21, 2021

              Details:

              VENCLEXTA®/VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.